Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo

HIGHLIGHTS

• who: Mu00e9lanie Demeules from the Pasteur Institute of Iran, Iran Anhui Medical University, China have published the article: Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo, in the Journal: (JOURNAL)
• what: The authors used the AAVnano methodological approach , to evaluate the anti-tumor effect of nanobody-based biologics designed to block or to potentiate P2X7 functions. The authors demonstrate that blocking P2X7 in the LLC lung carcinoma model had no effect on the tumor progression and mice survival, in line with the very low surface expression of P2X7 in this . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.